Broaddus Kristyn D, Tillson D Michael, Lenz Stephen D, Niemeyer Glenn P, Brawner William R, Welch Janet A, Lothrop Clinton D
Department of Clinical Sciences and Scott-Ritchey Research Center, College of Veterinary Medicine, Auburn University, AL 36849, USA.
Vet Surg. 2006 Feb;35(2):125-35. doi: 10.1111/j.1532-950X.2006.00123.x.
To evaluate allograft histopathology in dog leukocyte antigen (DLA)-mismatched dogs undergoing renal transplantation, with transient immunosuppression.
Prospective study.
Ten healthy adult mongrel dogs.
Reciprocal renal transplantation and bilateral nephrectomy were performed. Immune conditioning consisted of nonmyeloablative (200 cGy), total body irradiation (TBI), bone marrow transplantation (BMT; 7 dogs), cyclosporine (CSA; 15 mg/kg every 12 hours), mycophenolate mofetil (MMF; 10 mg/kg every 12 hours) and intermittent prednisone (1 mg/kg every 12-24 hours). Biopsies were collected at transplantation, during full immunosuppression (44-90 days), and once medications were reduced or discontinued (228-580 days). Biopsies were evaluated for interstitial, tubular, vascular, and glomerular lesions. Blood urea nitrogen, creatinine, serum CSA concentrations, and clinical score were determined at each biopsy.
Seven dogs survived >200 days (mean, 380 days). Transient CSA toxicity was suspected in 6 dogs. Lymphocytic, plasmacytic interstitial inflammation, and tubulitis progressed when immunosuppressive medications were decreased. All 7 dogs had histologic lesions consistent with some degree of allograft rejection at study end.
Nonmyeloablative TBI, BMT, and short-term immunosuppression with CSA, MMF, and prednisone allowed renal allograft function and dog survival for >200 days. It appears unlikely that total drug withdrawal will be possible in unrelated DLA-mismatched dogs using this protocol.
Transient immunosuppression with MMF, CSA, and prednisone along with BMT and nonmyeloablative TBI may make kidney transplantation a clinical reality for treatment of kidney failure in dogs. Initiating both MMF and CSA at lower dosages may potentially eliminate early renal allograft injury.
评估接受肾移植且采用短期免疫抑制的犬白细胞抗原(DLA)不匹配犬的同种异体移植组织病理学情况。
前瞻性研究。
10只健康成年杂种犬。
进行双侧肾脏移植及双侧肾切除术。免疫预处理包括非清髓性(200 cGy)全身照射(TBI)、骨髓移植(BMT;7只犬)、环孢素(CSA;每12小时15 mg/kg)、霉酚酸酯(MMF;每12小时10 mg/kg)及间歇性泼尼松(每12 - 24小时1 mg/kg)。在移植时、完全免疫抑制期间(44 - 90天)以及药物减量或停药时(228 - 580天)采集活检样本。对活检样本进行间质、肾小管、血管及肾小球病变评估。每次活检时测定血尿素氮、肌酐、血清CSA浓度及临床评分。
7只犬存活超过200天(平均380天)。6只犬疑似出现短暂性CSA毒性反应。当免疫抑制药物减量时,淋巴细胞、浆细胞性间质炎症及肾小管炎加重。研究结束时,所有7只犬均有与一定程度同种异体移植排斥相符的组织学病变。
非清髓性TBI、BMT以及CSA、MMF和泼尼松的短期免疫抑制可使同种异体肾移植功能维持且犬存活超过200天。采用该方案,在不相关的DLA不匹配犬中似乎不太可能完全停药。
MMF、CSA和泼尼松的短期免疫抑制联合BMT及非清髓性TBI可能使犬肾移植成为治疗犬肾衰竭的临床可行方法。以较低剂量起始MMF和CSA可能潜在地消除早期同种异体肾移植损伤。